Bausch Health Companies Inc BHC

Bausch Health Companies Inc. es una empresa farmacéutica especializada y de dispositivos médicos. La compañía se dedica al desarrollo, fabricación y comercialización de una variedad de productos farmacéuticos de marca, genéricos y de marca genérica, productos de venta libre (OTC) y dispositivos médicos (lentes de contacto, lentes intraoculares, equipos quirúrgicos oftálmicos y dispositivos estéticos), que se comercializan directa o indirectamente en más de 100 países. Sus segmentos incluyen Bausch + Lomb, Salix, Ortho Dermatologics, International Rx y Diversified Products. El segmento de Bausch + Lomb consiste en ventas en Estados Unidos de productos de cuidado de la visión, consumo, quirúrgicos y oftalmológicos de Bausch + Lomb. El segmento de Salix consiste en ventas en Estados Unidos de productos de gastroenterología (GI). El segmento de Ortho Dermatologics consiste en ventas en Estados Unidos de productos dermatológicos de Ortho Dermatologics y ventas globales de dispositivos estéticos médicos de Solta.

• Zacks Investment Research 2 oct

  4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike

  With Wall Street experiencing volatility due to Middle East tensions and inflation concerns, the Federal Reserve has raised interest rates for the first time in three years and hints at further hikes. The article recommends four low-beta defensive healthcare stocks as potential investments during this uncertain period: Abbott Laboratories, Corcept Therapeutics, Precigen, and Bausch Health Companies.

  

• Zacks Investment Research 30 sept

  Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks

  Consumer confidence fell 6.7% to 81.9 in September 2026, hitting its lowest level since April 2014, driven by concerns about labor market conditions and Middle East geopolitical tensions. The Federal Reserve hiked interest rates by 25 basis points and hinted at further increases. In response, four defensive stocks from healthcare and consumer staples sectors are recommended: Bausch Health Companies, CareDx, Dole, and The Chefs' Warehouse.

  

• GlobeNewswire Inc. 28 sept

  Acne Vulgaris Market Set for Significant Growth During the Forecast Period (2026–2036), Amid Rising Disease Burden and Therapeutic Advances | DelveInsight

  The acne vulgaris market is expected to grow steadily through 2036, driven by increasing disease prevalence affecting 85% of adolescents and young adults, and a pipeline of emerging therapies. Key players including Ascletis Pharma, Sagimet Biosciences, AOB Pharma, and Kintor Pharmaceutical are developing novel treatments like Denifanstat (ASC40), TVB-3567, B244, and GT20029 to address unmet needs in moderate-to-severe and treatment-resistant acne. The U.S. holds the largest market share, with recent approvals including clascoterone (WINLEVI) and combination therapy CABTREO expanding treatment options.

  

• GlobeNewswire Inc. 18 sept

  Body Contouring Devices Market Expands as Non-Invasive Technology Reaches Untapped Male Demographic

  The global body contouring devices market is expected to grow from $2.41 billion in 2025 to $8.82 billion by 2035, with a CAGR of 13.84%. Non-invasive treatments dominate with 78.4% market share, driven by rising obesity rates and increasing demand for non-surgical aesthetic procedures. The U.S. market alone is projected to reach $2.74 billion by 2035. Key growth drivers include expanding male demographics, multi-modal technology platforms, and rising social media influence on aesthetic awareness.

  

• Zacks Investment Research 14 sept

  4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike

  With inflation remaining stubbornly high at 3.4% annually and a 90% probability of a Federal Reserve rate hike expected, the article recommends four defensive healthcare stocks: Amgen, Bausch Health, CareDx, and Centene. CareDx and Centene are expected to deliver over 100% earnings growth this year, while all four stocks have seen improved earnings estimates over the past 60 days.